Bobanga Iuliana D, Petrosiute Agne, Huang Alex Y
Departments of General Surgery, School of Medicine, University Hospital Case Medical Center/Case Western Reserve University, Cleveland, OH 44106, USA.
Departments of Pediatrics, School of Medicine, University Hospital Case Medical Center/Case Western Reserve University, Cleveland, OH 44106, USA.
Vaccines (Basel). 2013 Dec 1;1(4):444-62. doi: 10.3390/vaccines1040444.
We are witnessing a new era of immune-mediated cancer therapies and vaccine development. As the field of cancer vaccines advances into clinical trials, overcoming low immunogenicity is a limiting step in achieving full success of this therapeutic approach. Recent discoveries in the many biological roles of chemokines in tumor immunology allow their exploitation in enhancing recruitment of antigen presenting cells (APCs) and effector cells to appropriate anatomical sites. This knowledge, combined with advances in gene therapy and virology, allows researchers to employ chemokines as potential vaccine adjuvants. This review will focus on recent murine and human studies that use chemokines as therapeutic anti-cancer vaccine adjuvants.
我们正在见证免疫介导的癌症治疗和疫苗开发的新时代。随着癌症疫苗领域进入临床试验阶段，克服低免疫原性是实现这种治疗方法全面成功的一个限制步骤。趋化因子在肿瘤免疫学中的多种生物学作用的最新发现，使得它们可被用于增强抗原呈递细胞（APC）和效应细胞向合适解剖部位的募集。这一知识，再结合基因治疗和病毒学的进展，使研究人员能够将趋化因子用作潜在的疫苗佐剂。本综述将聚焦于近期使用趋化因子作为治疗性抗癌疫苗佐剂的小鼠和人体研究。
Zotero 插件